ClinicalTrials.gg
CompletedNCT05378776STAGEUpdated May 18, 2025

Sucrose at Triage for Acute Gastroenteritis Episode in Children

An interventional study of sucrose and Standard rehydration solution in Gastroenteritis Acute and Vomiting, sponsored by Jocelyn Gravel. Completed at 1 site in Canada. Open to participants aged 6 Months to 83 Months. Per ClinicalTrials.gov, last updated 2025-05-18.

Sponsored by Jocelyn Gravel · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
6 Months to 83 Months
Sex
All
01

Study summary

Background: Acute viral gastroenteritis is a very common pediatric medical condition that results in a large number of emergency department (ED) visits. Fasting-induced ketosis has been suggested to contribute to nausea and vomiting in children with VGE. To date, there is no data on the impact of oral sucrose intake during oral rehydration.

Objective: The aim of this study is to assess the impact of providing a sucrose solution at triage to young children with suspected acute viral gastroenteritis on the amount of rehydration solution intake in the first 2 hours. We will also assess the proportion of discharge after initial medical evaluation, the proportion of oral rehydration failure, the number of vomiting episodes per patient, ondansetron administration, the time between the intervention and ED discharge, the time between the first medical contact and ED discharge and return visits within 48 hours.

Methods:

This study will be a double-blind randomized controlled trial. Recruitment will take place in a tertiary pediatric ED. Participants will be all children who present to the ED with suspected acute acute viral gastroenteritis with at least three vomiting in the previous 24 hours. The intervention will consist in giving 1.5 ml/kg of a sucrose solution composed of diluted juice with added table sugar (3.5g of sucrose/10 ml) compared with 1.5 ml/kg of diluted juice (0.5g of sucrose/10 mL, standard of care in our ED). Following that, all participants will be rehydrated with 15 mL of diluted juice every 15 minutes or more if tolerated. The primary outcome will be the amount of rehydration solution (ml) absorbed in the first two hours following intervention. Secondary outcomes will include disposition after initial medical evaluation, oral rehydration failure, the number of vomiting, ondansetron administration, the time between the intervention and ED discharge, the time between the first medical contact and ED discharge and return visits within 48 hours. The primary analysis will be the difference in the amount of tolerated oral rehydration between the two groups. Based on a preliminary study of children suffering from VGE, it was estimated that the recruitment of 238 participants would provide a power of 80% to identify a difference of 15 ml between the two groups.

Expected results:

We hope that this study will demonstrate that an oral sucrose solution given at triage to children presenting with symptoms compatible with acute acute viral gastroenteritis promotes oral hydration and consequently increases the total amount of rehydration solution tolerated by children.

02

Conditions studied

  • Gastroenteritis Acute
  • Vomiting

Keywords

  • children
  • sucrose
  • emergency department
  • triage
03

In context

Vomiting

793 studies on the registry are indexed under Vomiting; 99 are open to participants now.

This study's enrollment of 240 is above the median of 103 across 673 interventional studies indexed under Vomiting.

Browse Vomiting studies →

Lead sponsor

This is the only study on the registry with Jocelyn Gravel as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 83 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 6 months to 6 years. We will restrict to this age group to have a more homogenous group.
  • At least 3 non-bilious, non-bloody, vomiting in the last 24 hours
  • No other diagnostic more likely than acute viral gastroenteritis suspected at triage

Exclusion criteria

Exclusion Criteria:

  • Severe dehydration (based on poor capillary refill or hypotension)
  • Hypoglycemia identified by the triage nurse (\< 2,8 mmol)
  • Bilious or bloody vomiting
  • Chronic disease other than asthma
  • Previous inclusion in the study
  • Inability to obtain parental (language barrier, absence, etc.)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    Sucrose

    The experimental arm will receive 1.5 ml/kg of the sucrose solution at triage (once). The composition of the homemade sucrose solution used in our emergency department is 3.5 g of table sugar (sucrose) mixed with 10 ml of diluted juice (see standard arm description) to obtain a solution with the same appearance as the standard arm.

    Dietary Supplement: sucrose

  • Placebo comparator
    Control

    This group will receive 1.5 mL/kg of diluted juice composed of juice (apple or orange) and water in equal proportion once at triage. This solution contains 0.05 g/ml of sucrose for a total of 0.075 g/kg of sucrose (eight times less than the intervention arm).

    Dietary Supplement: Standard rehydration solution

Interventions

  • Dietary supplementsucrose

    The experimental arm will receive 1.5 ml/kg of the sucrose solution at triage (once). The composition of the homemade sucrose solution used in our emergency department is 3.5 g of table sugar (sucrose) mixed with 10 ml of water. For this double-blind study, we replaced water with diluted juice (see standard arm description) to obtain a solution with the same appearance as the standard arm. With the idea of correcting ketosis, we chose to provide the same amount of sugar as we do in hypoglycemia (0.4-0.5 g/kg of dextrose) to participants in the intervention group, which represents 1.5 ml/kg of the sucrose solution containing 0.4 g of sucrose/mL for a total of 0.6 g/kg of sucrose.

  • Dietary supplementStandard rehydration solution

    This group will receive 1.5 mL/kg of diluted juice composed of juice (apple or orange) and water in equal proportion once at triage. This solution contains 0.05 g/ml of sucrose for a total of 0.075 g/kg of sucrose (eight times less than the intervention arm).

06

What researchers measure

Primary outcomes

  1. Mean amount of tolerated oral rehydration in mL

    The total amount of rehydration solution tolerated during the two hours following intervention. This will be the amount of solution absorbed by the child without vomiting. In case of vomiting, the amount of solution absorbed will be the amount of solution tolerated after vomiting. In the few situations when the children will be discharged from the ED before two hours, we will collect the amount of solution tolerated before discharge.

    Time frame: 2 hours after intervention

Secondary outcomes

  1. Number of participants who needed an observation

    Patient who are not immediately discharged by the treating physician after the first evaluation

    Time frame: 2 hours

  2. Number of participants with oral rehydration failure

    Patient who need an intravenous rehydration during ED stay

    Time frame: 6 hours

  3. Mean number of vomiting

    Number of vomiting episode per patient during ED stay

    Time frame: 6 hours

  4. Number of participants who received ondansetron

    Number of patients who received ondansetron during ED stay

    Time frame: 6 hours

  5. Mean length of stay

    The time between the intervention and ED discharge

    Time frame: 24 hours

  6. Mean length of stay after physician evaluation

    The time between the first evaluation by a physician and ED discharge

    Time frame: 24 hours

  7. Number of participants who had a return visit

    return visit to the ED

    Time frame: 48 hours

07

Study locations

1 site
  • Sainte-Justine Hospital
    Montreal, Quebec H3T1C5, Canada
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05378776
Lead sponsor
Jocelyn Gravel
Responsible party
Jocelyn Gravel (Principal investigator, St. Justine's Hospital) — Sponsor-investigator
First posted
May 18, 2022
Start date
May 11, 2022
Primary completion
Dec 31, 2024
Completion
Dec 31, 2024
Last update
May 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sucrose

Start the discussion